The global cancer metabolism based therapeutics market, valued at USD 2.7 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 26.3 billion by 2035, with a CAGR of 24.3% during the forecast period 2026 to 2035. With respect to route of administration, oral route (close to 85%) dominates the current market. Based on target disease indication, in 2026, breast cancer captures the largest cancer metabolism based therapeutics market value (over 45%). In terms of geographical regions...

The global liquid biopsy market, valued at USD 8.20 billion in 2025, is projected to reach USD 9.49 billion in 2026 and USD 33.45 billion by 2035, representing a CAGR of 15.0% during the forecast period 2026 to 2035. Liquid biopsy solutions offer a minimally invasive and accessible method for early cancer detection and patient monitoring. This is primarily because of their superior ability to perform high-throughput multi-gene profiling, the ongoing reduction in sequencing costs, and its high se...

The global systemic lupus erythematosus market size, valued at USD 2,669 million in 2025, is projected to reach USD 2,471 million in 2026 and USD 6,547 million by 2035, representing a CAGR of 11.4% during the forecast period 2026 to 2035. Based on the route of administration, intravenous route captures the largest share (close to 70%) of the current market; this trend is unlikely to change in the future. Amongst the types of therapy, combination therapies capture the most (nearly 95%) of the cur...

The global live cell encapsulation market, valued at USD 613 million in 2025, is projected to reach USD 642 million in 2026 and USD 1,787 million by 2035, representing a CAGR of 12.1% during the forecast period 2026 to 2035. In terms of therapeutic area, metabolic disorders are likely to hold the highest share (over 40%) of the future market share. Based on the type of payment, upfront payments capture the largest share (over 85%) of the current market. In terms of geographical regions, North Am...

The global next generation immune checkpoint inhibitors market, valued at USD 15.4 billion in 2025, is projected to reach USD 17.5 billion in 2026 and USD 20.9 billion by 2035. Based on type of molecule, biologics are likely to hold the highest market share (close to 97%), in the current year. Based on geographical regions, North America is projected to capture the majority share of the market, in 2035. In terms of sales forecast for therapies, Darzalex will hold the highest market share by secu...

The global ready to use pharmaceutical packaging market, valued at USD 13.7 billion in 2025, is projected to reach USD 15.0 billion in 2026 and USD 39.9 billion by 2035, with a CAGR of 11.5% during the forecast period 2026 to 2035. In terms of type of pre-sterilized / ready to use pharmaceutical packaging systems, closures secure 65% of the overall revenue share. In January 2026, Becton Dickinson and Company (BD) announced USD 110 million investment to expand its ready to use prefilled syringe p...

The global biopharmaceutical contract manufacturing market, valued at USD 28.0 billion in 2025, is projected to reach USD 31.0 billion in 2026 and USD 63.9 billion by 2035, with a CAGR of 8.3% during the forecast period 2026 to 2035. In terms of type of expression system used, mammalian expression systems currently hold around 80% of the market share, due to their superior ability to produce complex proteins by mimicking human biology. In terms of scale of operation, commercial scale segment cap...

The global antibody contract manufacturing market, valued at USD 19.0 billion in 2025, is projected to reach USD 21.2 billion in 2026 and USD 49.1 billion by 2035, with a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of the type of antibody manufactured, monoclonal antibodies currently capture (95%) of the market share due to the fact that monoclonal antibodies are highly specific, consistent in structure, and are usually produced in large quantities. Based on the therapeutic a...

The global radiopharmaceutical last-mile logistics market reached USD 1.20 billion in 2026 and is projected to reach USD 5.65 billion by 2040, growing at a CAGR of 11.7% over the forecast period 2026 to 2040, driven by time-critical nuclear medicine delivery growth. Based on Radiopharmaceutical Type, PET radiopharmaceuticals capture 33.0% market share in 2026, whereas theranostic radiopharmaceuticals register a 17.4% CAGR through 2040, driven by paired diagnostic and therapeutic oncology pathway...

The global mRNA vaccine and therapeutics market, valued at USD 9 million in 2026, is projected to reach USD 17,036 million by 2035, representing a high CAGR during the forecast period 2026 to 2035. In terms of geographical regions, North America holds 75% of the market share due to the growing research, favorable regulatory guidelines for approval of mRNA vaccines and therapeutics, and a strong presence of key mRNA developers. In January 2026, Moderna secured a strategic capital commitment of US...

The global photodynamic therapy market, valued at USD 672 million in 2025, is projected to reach USD 749 million in 2026 and USD 1,532 million by 2035, representing a CAGR of 8.3% during the forecast period 2026 to 2035. In terms of target indication, actinic keratosis holds the highest share (over 35%) of the market. According to American Cancer Society, there were 104,960 new cases of skin cancer reported in 2025 in the US alone, with high recurrence rates. For instance, basal cell carcinoma...

The global non-viral transfection reagents market, valued at USD 0.79 billion in 2025, is projected to reach USD 0.89 billion in 2026 and USD 2.01 billion by 2035, representing a CAGR of 9.5% during the forecast period 2026 to 2035. In October 2025, MaxCyte signed a platform licensing agreement with Moonlight Bio, granting non-exclusive research, clinical, and commercial rights to Moonlight Bio’s Flow Electroporation technology and ExPERT platform for scalable development and manufacturing of...

The biologics safety testing market size, valued at USD 4.9 billion in 2025, is projected to reach USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In terms of end-user, the pharmaceutical and biotechnology companies segment accounts for around 50% of the overall revenue share. North America is holding close to 40% of the market share due to its strong public and private investments, supportive regulations, and significant...

The global oral solid dosage manufacturing market, valued at USD 599 billion in 2025, is projected to reach USD 623 billion in 2026 and USD 861 billion by 2035, with a CAGR of 3.7% during the forecast period 2026 to 2035. Based on the type of packaging, blisters are likely to occupy the largest share of the market in 2035. Based on company size, large companies are anticipated to hold the highest market share (close to 75%) in 2026. In August 2025, Piramal Pharma Solutions announced the collabor...

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. In the future, hybrid manufac...

The global next generation RNA therapeutics market, is projected to reach USD 0.1 billion in 2029 and USD 2.7 billion by 2035, representing a CAGR of 63.1% during the forecast period 2029 to 2035. The US FDA Biologics License Application (BLA) Pathway: The US FDA regulates RNA therapeutics and vaccines as biologics under the Center for Biologics Evaluation and Research (CBER). In June 2025, the Data 2 Reality (D2R) initiative allocated USD 400,000 to fund pioneering projects in next-generation R...

The global cancer biologics market size, valued at USD 189 billion in 2025, is projected to reach USD 210 billion in 2026 and USD 442 billion by 2035, with a CAGR of 8.6% during the forecast period 2026 to 2035. In the past few years, drug-based interventions (including biologics and small molecules) have observed a rapidly expanding pipeline for various types of cancer. The increased focus on personalized cancer biologics therapy market has garnered the interest of several pharmaceutical compan...

The ADC cytotoxic payloads and warheads market, valued at USD 381.3 million in 2025, is projected to reach USD 469.3 million in 2026 and USD 720.2 million by 2035, representing a CAGR of 4.9% during the forecast period 2026 to 2035. According to the ADC cytotoxic payloads and warheads market forecast, the commercial ADCs sub-segment dominates the market (90%), driven by the increased demand for commercialized ADCs owing to their efficacy and safety profile. In 2035, Europe’s ADC cytotoxic payl...

The global RNA extraction and RNA purification market size is estimated to reach $5.6 billion by 2035. Though these kits offer various significances, there are several limitations associated with the automation of RNA extraction, such as sample type compatibility, RNA integrity, yield purity, and inaccurate representation of gene expression. To address these concerns, extensive research has been carried out by key players to identify / develop strategies to improve RNA extraction and RNA purific...

The global complement inhibitors market size, valued at USD 12.56 billion in 2025, is projected to reach USD 14.30 billion in 2026 and USD 28.65 billion by 2035, with a CAGR of 8% during the forecast period 2026 to 2035. In terms of geographical regions, North America is holding 68% of the complement inhibitors market share due to the growing research, favorable regulatory guidelines, and a strong presence of top complement inhibitors companies. In January 2025, Teva and Samsung Bioepis enter in...